Beyond mRNA Vaccines – Emerging Applications For Lipid Nanoparticle Delivery Technologies

Source: Evonik Corporation

The potential of lipid nanoparticle-based drug delivery technologies to enable a new generation of medicines was made clear to all in 2020.  The first two mRNA vaccines for COVID-19 were rapidly developed and authorized for emergency use after clinical trials demonstrated exceptional levels of efficacy.  But beyond the use of liposomes for small molecule drugs to target systemic diseases such as tumors, and LNPs for vaccines, what other applications are now being explored for such delivery technologies? In this interview, we hear from Dr. Jay Natarajan, Director of R&D, for Evonik’s competence center for LNP technology in Vancouver, Canada.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online